Evidence map›Paper›PMID 27713229›Full record

ArticlePharmaceuticals (Basel, Switzerland)2009

Combination Therapy with Olmesartan and Amlodipine in the Treatment of Hypertension.

Menco G Niemeijer, Ton J Cleophas

Abstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Menco G NiemeijerAcademic Medical Centre, Amsterdam, The Netherlands. m.g.niemeyer@gmail.com.
Ton J CleophasAlbert Schweitzer Hospital, Dordrecht, The Netherlands. tj.cleophas@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCombination therapy with antihypertensive agents utilises different mechanisms of action and may be responsible for a more effective decrease in blood pressure.

objectiveTo review the recently published trials on efficacy and safety of the combination therapy with olmesartan and amlodipine.

resultsThe double-blind American COACH (Combination of Olmesartan Medoxomil and Amlopdine Besylate in Controlling High Blood Pressure) study (2008) showed in 1,940 patients that after eight weeks of treatment the BP goals were most frequently achieved in the 'combination therapy group', with 56.3% (54.1-58.5%) and 54.0% (51.8-56.2%) of patients reaching adequate blood pressure of.

Indexed as

amlodipinecombination therapyhypertensionolmesartan

Identifiers

PMID27713229
PMCPMC3978537

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.